TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16965206

Group type: EXPERIMENTAL
Intervention: 4-step treatment algorithm (washout period, anti-depressant monotherapy, lithium addition, treatment with a nonselective monoamine oxidase inhibitor, electroconvulsive therapy)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 4-step treatment algorithm
Number of subjects: 203

Group type: COMPARATOR
Intervention: Antidepressant monotherapy
Number of subjects: 203
Study: 15577441

Group type: EXPERIMENTAL
Intervention: Interfraction interval (IFI) of 4.5-5.0 hours
Number of subjects: 536

Group type: COMPARATOR
Intervention: Interfraction interval (IFI) of 5.5-6.0 hours
Number of subjects: 536
Study: 12411356

Group type: EXPERIMENTAL
Intervention: Ionisation sensor with a zinc battery; ionisation sensor with a zinc battery and pause button; ionisation sensor with a lithium battery and pause button; optical sensor with a lithium battery; or optical sensor with a zinc battery
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: Ionisation sensor with a lithium battery
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: Households occupied by smokers
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: Presence of a smoker in the household
Number of subjects: 2145
Study: 9798804

Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. for 1 week (RbcCT)
Number of subjects: 295

Group type: COMPARATOR
Intervention: RBC 400 mg b.d. plus clarithromycin 500 mg b.d. for 2 weeks (RbcC)
Number of subjects: 295
Study: 7644253

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral mediation model
Number of subjects: 100
Study: 2665352

Group type: EXPERIMENTAL
Intervention: ICRC vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG (control)
Number of subjects: 0
Study: 360232

Group type: EXPERIMENTAL
Intervention: piracetam (Nootropil) 2400 mg/day
Number of subjects: 56

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56
Study: 30630559

Group type: EXPERIMENTAL
Intervention: Dezocine-remifentanil intravenous anaesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Midazolam-remifentanil intravenous anaesthesia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 28667118

Group type: EXPERIMENTAL
Intervention: GIP
Number of subjects: 8

Group type: COMPARATOR
Intervention: GIP(3-30)NH2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GIP + GIP(3-30)NH2
Number of subjects: 8
Study: 26116874

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 806
Study: 23692891

Group type: EXPERIMENTAL
Intervention: Remote magnetic control (RMC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual catheter control (MCC)
Number of subjects: 30
Study: 21314280

Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Posterolateral fusion (PLF)
Number of subjects: 50
Study: 19803563

Group type: EXPERIMENTAL
Intervention: Dissonance intervention
Number of subjects: 306

Group type: COMPARATOR
Intervention: Psychoeducational brochure control
Number of subjects: 306
Study: 17356528

Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg/day)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Lifestyle modification counseling alone
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Sibutramine plus lifestyle modification counseling
Number of subjects: 224

Group type: COMPARATOR
Intervention: Sibutramine alone
Number of subjects: 224
Study: 15269618

Group type: EXPERIMENTAL
Intervention: Fermented infant formula (FF) with Bifidobacterium breve C50 and Streptococcus thermophilus 065
Number of subjects: 971

Group type: COMPARATOR
Intervention: Standard infant formula (SF)
Number of subjects: 971
Study: 10997483

Group type: EXPERIMENTAL
Intervention: tibolone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: estrogen/glucocorticoid combination
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 39
Study: 8752077

Group type: EXPERIMENTAL
Intervention: Actual length of stay (longer duration)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Planned duration (3 or 6 months)
Number of subjects: 444
Study: 1580345

Group type: EXPERIMENTAL
Intervention: Short-term group treatment program for abusive husbands
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of untreated abusive husbands
Number of subjects: 0
Study: 3882059

Group type: EXPERIMENTAL
Intervention: High energy feeds (3.6 MJ/L, 87 kcal/100 ml)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard energy feeds (2.7 MJ/L, 65 kcal/100 ml)
Number of subjects: 17
Study: 31177994

Group type: EXPERIMENTAL
Intervention: Self-help diet and activity intervention with telephone-based dietitian support
Number of subjects: 62

Group type: COMPARATOR
Intervention: Wait-list mini-intervention group
Number of subjects: 62
Study: 28210843

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: GS (Gemcitabine plus S-1)
Number of subjects: 795
Study: 26918239

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) plus timolol gel 0.05%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL)
Number of subjects: 30
Study: 23581532

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 1856

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 1856

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1856
Study: 21739686

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 60
Study: 19370466

Group type: EXPERIMENTAL
Intervention: Diclofenac 3% gel followed by ALA-PDT
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo gel followed by ALA-PDT
Number of subjects: 10
Study: 16911579

Group type: EXPERIMENTAL
Intervention: Mitral isthmus line (ML) recovery
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Roof-line (RL) recovery
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Reablation of lines
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Conduction delay
Number of subjects: 48
Study: 15224297

Group type: EXPERIMENTAL
Intervention: 18 Gy radiation dose
Number of subjects: 180

Group type: COMPARATOR
Intervention: 15 Gy radiation dose
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 11203643

Group type: EXPERIMENTAL
Intervention: Laser-welded titanium framework
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional cast framework
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Titanium framework prosthesis (group B)
Number of subjects: 42
Study: 9315594

Group type: EXPERIMENTAL
Intervention: Estradiol 17 beta
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 8482557

Group type: COMPARATOR
Intervention: 6 cycles of cyclophosphamide, Adriamycin, and cisplatin (CAP)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: 12 cycles of cyclophosphamide, Adriamycin, and cisplatin (CAP)
Number of subjects: 202

Group type: COMPARATOR
Intervention: 6 cycles of CAP (after second-look laparotomy)
Number of subjects: 202
Study: 3915461

Group type: EXPERIMENTAL
Intervention: Tenoxicam 1.2 mg/kg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tenoxicam 0.3 mg/kg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tenoxicam 0.6 mg/kg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Paracetamol 10 mg/kg
Number of subjects: 38
Study: 3239727

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (5 micrograms/kg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Atropine (10 micrograms/kg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No anticholinergic premedication
Number of subjects: 51
Study: 31850931

Group type: EXPERIMENTAL
Intervention: GED‐0301 (160 mg for 12 weeks followed by 40 mg continuously)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: GED‐0301 (alternating placebo with 40 or 160 mg every 4 weeks through week 52)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: GED‐0301
Number of subjects: 701
Study: 29605891

Group type: EXPERIMENTAL
Intervention: Risk assessment focused on non‐medical risk factors, lifestyle factors, and medical risk factors, with subsequent institution of risk‐specific care pathways and multidisciplinary consultation.
Number of subjects: 4302

Group type: EXPERIMENTAL
Intervention: Risk assessment and care pathways intervention
Number of subjects: 4302
Study: 28882161

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) under general anesthesia
Number of subjects: 110

Group type: COMPARATOR
Intervention: Deep brain stimulation (DBS) under local anesthesia
Number of subjects: 110
Study: 26333545

Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RDN)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 18
Study: 23710902

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 21539581

Group type: EXPERIMENTAL
Intervention: Emergency laparotomy for acute intestinal disease
Number of subjects: 70
Study: 18814099

Group type: EXPERIMENTAL
Intervention: Prostanoids, nonselective and selective endothelin-receptor antagonists, phosphodiesterase-V inhibitors
Number of subjects: 0
Study: 16870914

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (5 ppm) for 21 days or until extubation
Number of subjects: 793

Group type: COMPARATOR
Intervention: Placebo gas
Number of subjects: 793
Study: 14645934

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Brief Advice (BA)
Number of subjects: 191
Study: 10893362

Group type: EXPERIMENTAL
Intervention: Seratrodast, 40 mg/d
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 8831532

Group type: EXPERIMENTAL
Intervention: Tc 99m HMPAO-labeled leukocyte scintigraphy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 27
Study: 1419642

Group type: EXPERIMENTAL
Intervention: Competing risk method
Number of subjects: 2850

Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 2850
Study: 3837566

Group type: EXPERIMENTAL
Intervention: Modified holding therapy (MHT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 14
Study: 30772283

Group type: EXPERIMENTAL
Intervention: Thoracentesis guided by symptoms plus manometry
Number of subjects: 124

Group type: COMPARATOR
Intervention: Thoracentesis guided by symptoms only (control)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study: 29317347

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) program presenting natural scenes for 5 minutes
Number of subjects: 20
Study: 27759847

Group type: EXPERIMENTAL
Intervention: Biosimilar filgrastim (Fiprima)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Originator filgrastim
Number of subjects: 0
Study: 24253831

Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 μg
Number of subjects: 2019

Group type: COMPARATOR
Intervention: FF 100 μg
Number of subjects: 2019
Study: 22152659

Group type: EXPERIMENTAL
Intervention: Abstainers and light drinkers
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Heavy episodic drinkers
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Maximum alcohol consumption in college
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Prior drinking experience
Number of subjects: 437
Study: 20479702

Group type: EXPERIMENTAL
Intervention: Minimally invasive TLIF using the tubular retractor system
Number of subjects: 62

Group type: COMPARATOR
Intervention: Traditional open procedure
Number of subjects: 62
Study: 19080431

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich beverage group (n = 24)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo group (n = 27)
Number of subjects: 51
Study: 15937606

Group type: EXPERIMENTAL
Intervention: Vaginal Birth (VB)
Number of subjects: 999

Group type: COMPARATOR
Intervention: Caesarean Section (CS)
Number of subjects: 999
Study: 11477347

Group type: EXPERIMENTAL
Intervention: tacrolimus+MMF
Number of subjects: 223

Group type: COMPARATOR
Intervention: CsA+MMF
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: tacrolimus+AZA
Number of subjects: 223
Study: 9570244

Group type: EXPERIMENTAL
Intervention: Triple therapy with metronidazole (500 mg twice daily for 2 weeks), amoxycillin (500 mg three times daily for 2 weeks), and omeprazole (20 mg once daily for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dual therapy with amoxycillin (500 mg three times daily for 2 weeks) and omeprazole (20 mg once daily for 8 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dual therapy
Number of subjects: 60
Study: 7978442

Group type: COMPARATOR
Intervention: Nicardipine 0 micrograms.kg‐1.min‐1
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Nicardipine 1 micrograms.kg‐1.min‐1
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Nicardipine 2 micrograms.kg‐1.min‐1
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Nicardipine 3 micrograms.kg‐1.min‐1
Number of subjects: 47
Study: 2659003

Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl magnesium glutamate (NAAGA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30325764

Group type: EXPERIMENTAL
Intervention: Immediate ART for 48 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 82
Study: 28581818

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg a.m. and placebo p.m. (n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: metformin 500 mg bid (n=8)
Number of subjects: 16
Study: 25462650

Group type: EXPERIMENTAL
Intervention: Substance-related addictions (alcohol, tobacco, marijuana, cocaine)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Behavioral addictions (problematic gambling, eating, shopping, sexual behavior, video gaming, work)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: General public perceptions
Number of subjects: 4000
Study: 24115597

Group type: EXPERIMENTAL
Intervention: Automated localization of the ascending aorta (AAo) and descending aorta (DAo) using phase contrast MRI.
Number of subjects: 1884

Group type: EXPERIMENTAL
Intervention: Automated flow volume measurement for AAo and DAo.
Number of subjects: 1884
Study: 22840621

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non‐invasive sham acupuncture
Number of subjects: 20
Study: 19419254

Group type: EXPERIMENTAL
Intervention: Clevidipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clevidipine-nitroglycerin
Number of subjects: 0
Study: 17907081

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GnRH-analoga and antiandrogens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytostatic therapy
Number of subjects: 0
Study: 15198380

Group type: EXPERIMENTAL
Intervention: Cyanocobalamin, 1 mg daily for 7 days, and 5 mg on the eighth day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo injection daily for 8 days
Number of subjects: 20
Study: 11740975

Group type: EXPERIMENTAL
Intervention: Hyperventilation challenge test (30 breaths/min for 4 min)
Number of subjects: 125
Study: 9554677

Group type: EXPERIMENTAL
Intervention: IVAC 4200 BP performed by trained investigators (research automated [RA])
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: IVAC 4200 BP performed by ward personnel (ward automated [WA])
Number of subjects: 145

Group type: COMPARATOR
Intervention: Mercury manometer (MM)
Number of subjects: 145
Study: 8300656

Group type: EXPERIMENTAL
Intervention: Non-reamed locked nailing
Number of subjects: 29

Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 29
Study: 2499825

Group type: EXPERIMENTAL
Intervention: Topical phenytoin (PHT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 31169373

Group type: EXPERIMENTAL
Intervention: Negative images in the background during repeated displays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive images in the background during repeated displays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral images in the background during repeated displays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Removal of affective background images in Phase 2
Number of subjects: 0
Study: 29774521

Group type: EXPERIMENTAL
Intervention: PAN + BTZ + DEX
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo + BTZ + DEX
Number of subjects: 147
Study: 28646924

Group type: EXPERIMENTAL
Intervention: Household-level prophylaxis with single-dose ciprofloxacin
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Village-wide prophylaxis with single-dose ciprofloxacin
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 400
Study: 26369640

Group type: EXPERIMENTAL
Intervention: 0.5 Gy single dose
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 1.0 Gy single dose
Number of subjects: 112
Study: 23351188

Group type: EXPERIMENTAL
Intervention: GM1 (100 mg once daily for 3 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no neuroprotective agents)
Number of subjects: 120
Study: 20937617

Group type: EXPERIMENTAL
Intervention: 50 µL of the essential oil
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 20003436

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg per os daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Subcutaneous interferon beta-1b every other day
Number of subjects: 80
Study: 17261601

Group type: EXPERIMENTAL
Intervention: LT vaccine patch (50 microg) administered on days 0 and 21
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral ETEC challenge (LT+ ST+ E2447A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral cholera toxin B subunit-containing cholera vaccine
Number of subjects: 60
Study: 15059332

Group type: EXPERIMENTAL
Intervention: Stenting alone (Group A, n = 27)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Stenting followed by radiotherapy and/or chemotherapy (Group B, n = 26)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Stenting followed by radiotherapy and/or chemotherapy (Group B)
Number of subjects: 53
Study: 11224828

Group type: EXPERIMENTAL
Intervention: Oseltamivir 2 mg/kg/dose twice daily for 5 days
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 695

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695
Study: 8968633

Group type: EXPERIMENTAL
Intervention: Exposure therapy with ritual prevention
Number of subjects: 46
Study: 2302538

Group type: EXPERIMENTAL
Intervention: Toe-up or toe-down tilts of a platform (perturbations stretching the soleus muscle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toe-up or toe-down tilts of a platform (perturbations stretching the tibialis anterior muscle)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standing and holding onto a frame
Number of subjects: 0

Group type: COMPARATOR
Intervention: Translations (forward and backward) stretching the same leg muscle
Number of subjects: 0
Study: 6776577

Group type: EXPERIMENTAL
Intervention: Alcohol (0.65 g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined alcohol + tobacco (4 cigarettes + 0.65 g/kg ethyl alcohol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tobacco (4 cigarettes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined alcohol + tobacco
Number of subjects: 0
Study: 31262292

Group type: EXPERIMENTAL
Intervention: Palonosetron (PALO)
Number of subjects: 0
Study: 27924388

Group type: EXPERIMENTAL
Intervention: Robotic simulator
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laparoscopic simulator
Number of subjects: 40
Study: 24408084

Group type: EXPERIMENTAL
Intervention: SYNTAX score tertile (SS >12)
Number of subjects: 2627

Group type: EXPERIMENTAL
Intervention: SYNTAX score tertile (SS = 7-12)
Number of subjects: 2627

Group type: EXPERIMENTAL
Intervention: SYNTAX score tertile (SS <7)
Number of subjects: 2627

Group type: EXPERIMENTAL
Intervention: SYNTAX score tertile (SS >32)
Number of subjects: 2627

Group type: EXPERIMENTAL
Intervention: SYNTAX score tertile (SS = 23-32)
Number of subjects: 2627

Group type: COMPARATOR
Intervention: SYNTAX score tertile (SS <22)
Number of subjects: 2627
Study: 25310749

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pamphlet education
Number of subjects: 100
Study: 22748849

Group type: EXPERIMENTAL
Intervention: Fibrin-based biological adhesive applied to the suture line
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no adhesive applied)
Number of subjects: 104
Study: 20467943

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/RTV)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/RTV)
Number of subjects: 599
Study: 17594297

Group type: EXPERIMENTAL
Intervention: Self-selected distraction
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study: 16179043

Group type: EXPERIMENTAL
Intervention: Atropine (20 microg.kg(‐1)) + Remifentanil (1 microg.kg(‐1) bolus followed by 0.25 microg.kg(‐1).min(‐1) for 10 min, then 0.5 microg.kg(‐1).min(‐1) for 10 min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Remifentanil (1 microg.kg(‐1) bolus followed by 0.25 microg.kg(‐1).min(‐1) for 10 min, then 0.5 microg.kg(‐1).min(‐1) for 10 min)
Number of subjects: 40
Study: 12240783

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 894

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 894
Study: 10404769

Group type: EXPERIMENTAL
Intervention: E2 (2 mg micronised oestradiol daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: E2 + P (sequentially combined with a progestagen on 14 days of each cycle)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60